ClassID:

20986

A61K38/2228 - CPC Classification

Classification description:

Medicinal preparations containing peptides; Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans; Hormones Corticotropin releasing factor [CRF] (Urotensin)

Recent Application in this class:
#1
20250243255
2025-07-31

CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY

#2
20230310471
2023-10-05

METHODS, DEVICES, AND SYSTEMS FOR TREATING LENS PROTEIN AGGREGATION DISEASES

#3
20230233650
2023-07-27

NOVEL FATTY ACID MODIFIED UROCORTIN 2 DERIVATIVES AND THE USES THEREOF

#4
20210379158
2021-12-09

METHOD FOR PREVENTING OR TREATING HEART FAILURE BY ADMINISTERING A MEDICAMENT CONTAINING AN ANTAGONIST OF CORTICOTROPIN RELEASING HORMONE RECEPTOR 2 (CRHR2)

#5
20210346621
2021-11-11

INTRANASAL ADMINISTRATION

#6
20200231708
2020-07-23

Polypeptides which bind C-X-C chemokine receptor type 4 (CXCR4) and methods of treating or reducing the risk of fibrosis and cancer

#7
20190367945
2019-12-05

Method of treating type I diabetes using an AAV vector encoding uracortin 2

#8
20190336542
2019-11-07

SYNTHETIC BACTERIA AND METHODS OF USE

#9
20190250173
2019-08-15

METHODS FOR DETERMINING WHETHER A PATIENT IS LIKELY TO BENEFIT FROM TREATMENT WITH A THERAPEUTIC FORMULATION

#10
20190160151
2019-05-30

Method for preventing or treating heart failure by administering a medicament containing an antagonist of corticotropin releasing hormone receptor 2 (CRHR2)

#11
20190125992
2019-05-02

INTRANASAL ADMINISTRATION

#12
20190083455
2019-03-21

METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS

#13
20180271945
2018-09-27

UROCORTIN 2 ANALOGS AND USES THEREOF

#14
20180221450
2018-08-09

Formulation Comprising A Stabilized Complex Of Corticotropin Releasing Hormone And Alpha-2 Macroglobulin

#15
20180072816
2018-03-15

CXCR4 binding molecules and methods of use thereof

#16
20180016318
2018-01-18

Fatty acid modified urocortin-2 analogs for the treatment of diabetes and chronic kidney disease

#17
20180010148
2018-01-11

Method of treating type I diabetes using an AAV vector encoding uracortin 2

#18
20170326166
2017-11-16

COMPOSITIONS AND METHODS FOR TREATING PITUITARY TUMORS

#19
20170182129
2017-06-29

SYSTEMIC DELIVERY OF VIRUS VECTORS ENCODING UROCORTIN-2 AND RELATED GENES TO TREAT DIABETES-RELATED CARDIAC DYSFUNCTIONS AND CONGESTIVE HEART FAILURE

#20
20160375102
2016-12-29

UROCORTIN-III AND USES THEREOF

#21
20160206701
2016-07-21

Formulation comprising a stabilized complex of corticotropin releasing hormone and alpha-2 macroglobulin

#22
20160166651
2016-06-16

SYSTEMIC DELIVERY OF VIRUS VECTORS ENCODING UROCORTIN-2 AND RELATED GENES TO TREAT DIABETES-RELATED CARDIAC DYSFUNCTIONS AND CONGESTIVE HEART FAILURE

#23
20160022780
2016-01-28

UROCORTIN 2 ANALOGS AND USES THEREOF

#24
20150315257
2015-11-05

Urocortin 2 analogs and uses thereof

#25
20150165139
2015-06-18

Intranasal administration

#26
20150118287
2015-04-30

SYSTEMIC DELIVERY AND REGULATED EXPRESSION OF PARACRINE GENES FOR CARDIOVASCULAR DISEASES AND OTHER CONDITIONS

#27
20140113872
2014-04-24

Agonists and antagonists of the urotensinergic system

#28
20140072530
2014-03-13

TREATMENT OF HIV

#29
20130344102
2013-12-26

FORMULATION

#30
20130210710
2013-08-15

TREATMENT OF HIV

#31
20130203669
2013-08-08

MEDICAMENT

#32
20130123177
2013-05-16

Method of treating brain injury

#33
20130109621
2013-05-02

Methods for increasing insulin secretion by co-stimulation of corticotropin-releasing factor receptors

#34
20120270792
2012-10-25

Urocortin-III and uses thereof

#35
20120238509
2012-09-20

UROCORTIN 2 ANALOGS AND USES THEREOF

#36
20120220533
2012-08-30

Modulating neuromuscular junction density changes in botulinum-toxin treated tissue

#37
20120208745
2012-08-16

TREATMENT OF HIV

#38
20110105397
2011-05-05

METHOD FOR TREATING HEART FAILURE WITH STRESSCOPIN-LIKE PEPTIDES

#39
20110053827
2011-03-03

INTRANASAL ADMINISTRATION

#40
20100278743
2010-11-04

Methods for treatment and prevention of tauopathies and amyloid beta amyloidosis by modulating CRF receptor signaling

#41
20100203048
2010-08-12

METHODS OF USING CORTICOTROPIN-RELEASING FACTOR FOR THE USE OF THE TREATMENT OF CANCER

#42
20100196389
2010-08-05

Methods of using corticotropin-releasing factor for the use of the treatment of cancer

#43
20100120662
2010-05-13

Glucose uptake modulator and method for treating diabetes or diabetic complications

#44
20100113341
2010-05-06

METHODS OF USING CORTICOTROPIN-RELEASING FACTOR FOR THE TREATMENT OF CANCER

#45
20090291060
2009-11-26

Treatment of HIV

#46
20090156493
2009-06-18

Urocortin-III and uses thereof

#47
20090035298
2009-02-05

METHODS TO TREAT ALZHEIMER'S DISEASE OR OTHER AMYLOID BETA ACCUMULATION ASSOCIATED DISORDERS

#48
20080207500
2008-08-28

Medicament

#49
20080207490
2008-08-28

Glucose Uptake Modulator and Method for Treating Diabetes or Diabetic Complications

#50
20080161235
2008-07-03

Methods of increasing insulin sensitivity or decreasing insulin secretion by administering corticotropin releasing factor receptor-2 inhibitors

#51
20080113908
2008-05-15

Use of CRF receptor agonists for the treatment or Prophylaxis of diseases, for example Neurodegenerative diseases

#52
20070275102
2007-11-29

METHOD OF AFFECTING SLEEP AND SLEEP-RELATED BEHAVIORS

#53
20070149492
2007-06-28

METHOD OF AFFECTING SLEEP AND SLEEP-RELATED BEHAVIORS

#54
20060003937
2006-01-05

Urocortin-III and uses thereof

#55
19199523
2025-10-14

Kits for preparing and delivering purified corticotropin

#56
18818974
2025-02-25

Methods for storing and warming purified corticotropin compositions

#57
18634717
2024-10-01

Methods for storing and warming purified corticotropin compositions

#58
18495932
2024-05-07

Methods for storing and warming purified corticotropin compositions